Project Grant R01CA305985
Award Date
6/12/25
Completion Date
5/31/30
Dollars Obligated
$649K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Kentucky, USA
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) aims to investigate inhibition of the diacylglycerol lipase A (DAGLA) enzyme as a novel strategy to mitigate the nephrotoxicity (kidney damage) caused by the chemotherapy drug cisplatin. The $227,221 award to Virginia Commonwealth University, with a sub-award to the University of Missouri System, will fund research to determine if DAGLA inhibition protects the kidneys against cisplatin-induced...
The National Cancer Institute (NCI) awarded a $371,905 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to the University of Florida to support research on the role of Angiopoietin-like 4 (ANGPTL4) in clear cell renal cell carcinoma (CCRCC). The project aims to define ANGPTL4's functions in the CCRCC tumor microenvironment, evaluate the efficacy of combining anti-ANGPTL4 antibodies with immune checkpoint inhibitors in mouse models, and determine ANGPTL4's cancer...
The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
The University of Colorado-Denver was awarded a $375,134 Project Grant from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to investigate a novel approach for reducing off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize the innate immune response that can tighten epithelial barriers and limit nanoparticle deposition in healthy tissues, and to leverage this response to enhance delivery of chemotherapeutic agents to tumors...
The National Cancer Institute (NCI) awarded a $164,639 Project Grant (CFDA 93.394 - Cancer Detection and Diagnosis Research) to Brown University to develop a novel pipeline for kidney segmentation and registration based on deep learning techniques. The goal is to improve treatment efficacy and reduce recurrence rates for image-guided thermal ablation (IGTA), a minimally invasive cancer treatment. Specifically, the research will focus on detecting and mitigating potentially undetected...
The National Cancer Institute (NCI) awarded a $220,018 Project Grant under the Cancer Treatment Research Program (CFDA 93.395) to the University of Louisville. The grant will fund research to determine whether chemotherapy-induced changes in mitochondrial function and dynamics in hematopoietic stem and progenitor cells (HSPCs) contribute to the development of pro-metastatic myeloid cells. The study aims to investigate the role of mitochondrial reactive oxygen species (ROS) production and...
This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $192,888 to The Leland Stanford Junior University to develop a machine learning-based risk assessment model for predicting progressive chronic kidney disease (CKD) among patients undergoing cancer therapy. The project aims to address data gaps in assessing kidney function for this patient...
This Project Grant award of $305,000 from the National Science Foundation's (NSF) Technology, Innovation, and Partnerships (CFDA 47.084) program supports the development of a novel, non-invasive urine-based screening test for early detection of kidney cancer. The project aims to: Demonstrate the specificity and accuracy of a biomarker for detecting early-stage renal tumors in kidney cancer patients without symptoms. Demonstrate the effectiveness and accuracy of the test for detecting residual...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) is funding research to develop a therapeutic approach using dicarboxylic acids (DCAs) to prevent and treat acute kidney injury (AKI) and limit progression to chronic kidney disease (CKD). The $645,599 award to the University of Pittsburgh is supporting preclinical studies in animal models...
The National Cancer Institute (NCI) awarded a $154,642 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to the Sloan-Kettering Institute for Cancer Research. The grant, titled "Targeting the Evolving Immunopeptidome of Metastatic Colorectal Cancer," aims to systematically elucidate the evolving immunopeptidome from normal colon, primary tumor, and metastatic lesion patient-derived organoids (PDOs) through mass spectrometry. This will identify conserved...